SP Services (UK) Ltd

SP Services is an International supplier of first aid, medical, ambulance, paramedic and emergency rescue equipment, based at Bastion House in Telford, the company will be celebrating its 30th anniversary in business in 2019. 2015 proved to be a fantastic year for SP Services, with the launch of the new catalogue and with it the latest range of infection control friendly Parabag medical bags, Donway vacuum mattresses and splint and solution innovations for businesses. SP Services provide everything you need in an emergency, our customers work and are on call 24/7 which is why SP Services are too.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

ALTERITY THERAPEUTICS LAUNCHES ATH434 PHASE 2 CLINICAL TRIAL FOR THE TREATMENT OF PATIENTS WITH MULTIPLE SYSTEM ATROPHY

Alterity Therapeutics | June 03, 2022

news image

Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in New Zealand. MSA is a rare neurodegenerative disease. While it is similar to Parkinson's disease, MSA progresses m...

Read More

INDUSTRIAL IMPACT

EVAXION BIOTECH ANNOUNCES PUBLICATION OF CLINICAL DATA OF EVX-01 HEADING INTO PHASE 2B IN COLLABORATION WITH MERCK

Evaxion Biotech | January 27, 2022

news image

Evaxion Biotech A/S a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal OncoImmunology. The paper, entitled, “Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvan...

Read More

CELL AND GENE THERAPY

VIPERGEN PUBLISHES POWERFUL NEW DRUG DISCOVERY APPROACH FOR THE FIRST TIME, SCREENING DNA-ENCODED SMALL-MOLECULE LIBRARIES (DELS) INSIDE LIVING CELLS

Vipergen | February 18, 2021

news image

Vipergen ApS announced today a published study depicting a ground-breaking new medication revelation approach that empowers, interestingly, screening DNA-encoded small-molecule libraries (DELs) inside living cells. The study, published in the peer-reviewed Journal of the American Chemical Society, highlights the potential of Vipergen's Cellular Binder Trap Enrichment® (cBTE) technology to significantly grow the ability to discover novel small molecules, including against difficult-to-dru...

Read More

INDUSTRIAL IMPACT

QUANTUM GENOMICS SIGNS AN EXCLUSIVE LICENSE AND PRODUCTION AGREEMENT WITH GULF PHARMACEUTICALS INDUSTRIES JULPHAR

Quantum Genomics | December 06, 2021

news image

Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey. A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will...

Read More
news image

MEDICAL

ALTERITY THERAPEUTICS LAUNCHES ATH434 PHASE 2 CLINICAL TRIAL FOR THE TREATMENT OF PATIENTS WITH MULTIPLE SYSTEM ATROPHY

Alterity Therapeutics | June 03, 2022

Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in New Zealand. MSA is a rare neurodegenerative disease. While it is similar to Parkinson's disease, MSA progresses m...

Read More
news image

INDUSTRIAL IMPACT

EVAXION BIOTECH ANNOUNCES PUBLICATION OF CLINICAL DATA OF EVX-01 HEADING INTO PHASE 2B IN COLLABORATION WITH MERCK

Evaxion Biotech | January 27, 2022

Evaxion Biotech A/S a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal OncoImmunology. The paper, entitled, “Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvan...

Read More
news image

CELL AND GENE THERAPY

VIPERGEN PUBLISHES POWERFUL NEW DRUG DISCOVERY APPROACH FOR THE FIRST TIME, SCREENING DNA-ENCODED SMALL-MOLECULE LIBRARIES (DELS) INSIDE LIVING CELLS

Vipergen | February 18, 2021

Vipergen ApS announced today a published study depicting a ground-breaking new medication revelation approach that empowers, interestingly, screening DNA-encoded small-molecule libraries (DELs) inside living cells. The study, published in the peer-reviewed Journal of the American Chemical Society, highlights the potential of Vipergen's Cellular Binder Trap Enrichment® (cBTE) technology to significantly grow the ability to discover novel small molecules, including against difficult-to-dru...

Read More
news image

INDUSTRIAL IMPACT

QUANTUM GENOMICS SIGNS AN EXCLUSIVE LICENSE AND PRODUCTION AGREEMENT WITH GULF PHARMACEUTICALS INDUSTRIES JULPHAR

Quantum Genomics | December 06, 2021

Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey. A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will...

Read More